Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 9/20 | 0.35 |
| ▸ | ARG2 | P78540 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8713792 | 0.72 | MEN1 (0.32) | MEN1BLMKMT2A | |
| SCHEMBL20036523 | 0.71 | MAPT (0.34) | — | |
| SCHEMBL15062900 | 0.67 | ARG1 (0.42) | GRM8GRM6GRM2GRM3ARG1 | |
| SCHEMBL28686657 | 0.67 | ARG1 (0.42) | GRM8GRM6GRM2GRM3ARG1 | |
| SCHEMBL8610112 | 0.67 | MAPT (0.32) | — | |
| SCHEMBL2562686 | 0.66 | GRM2 (0.50) | GRM8GRM6GRM2GRM3GRM1 | |
| SCHEMBL25662353 | 0.66 | GRM2 (0.50) | GRM8GRM6GRM2GRM3GRM1 | |
| SCHEMBL8442483 | 0.62 | — | — | |
| SCHEMBL25660688 | 0.62 | — | — | |
| SCHEMBL25662364 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163505-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163505-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | GRM8 2995/4885GRM6 2313/4885GRM2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.